Advancing performance measures for use of medications in substance abuse treatment

Journal of Substance Abuse Treatment

Volumn 40, Issue 1, 2011, Pages 35-43

  Thomas, Cindy Parks ^a   Garnick, Deborah W ^a   Horgan, Constance M ^a   McCorry, Frank ^b   Gmyrek, Amanda ^c   Chalk, Mady ^d   Gastfriend, David R ^e   Rinaldo, Suzanne Gelber ^f   Albright, Joann ^g   Capoccia, Victor A ^h   Harris, Alex H S ⁱ   Harwood, Henrick J ^j   Greenberg, Pamela ^k   Mark, Tami L ^l   Un, Huong ^m   Oros, Marla ⁿ   Stringer, Mark ^o   Thatcher, James ^p  

^a BRANDEIS UNIVERSITY   (United States)

^b New York State Office of Alcoholism   (United States)

^c JBS International Inc   (United States)

^d TREATMENT RESEARCH INSTITUTE   (United States)

^e ALKERMES INC   (United States)

^f Avisa Group   (United States)

^g Magellan Health   (United States)

^h Closing the Addiction Treatment Gap   (United States)

ⁱ VETERANS AFFAIRS MEDICAL CENTER   (United States)

^j NASA HEADQUARTERS   (United States)

^k Association for Behavioral Health and Wellness   (United States)

^l THOMSON REUTERS   (United Kingdom)

^m AETNA   (United States)

ⁿ The Mosaic Group   (United States)

^o MISSOURI DEPARTMENT OF HEALTH AND SENIOR SERVICES   (United States)

^p Massachusetts Behavioral Health Partnership/ValueOptions   (United States)

more..

Author keywords

Medication; Performance; Pharmacotherapy; Quality; Treatment

Indexed keywords

ACAMPROSATE; BUPRENORPHINE; DISULFIRAM; NALTREXONE;

ALCOHOLISM; ARTICLE; CONTROLLED DRUG RELEASE; DRUG DEPENDENCE TREATMENT; HEALTH CARE COST; HEALTH CARE FINANCING; HEALTH CARE POLICY; HEALTH CARE QUALITY; HEALTH INSURANCE; HEALTH PROGRAM; HUMAN; MEDICAL EDUCATION; OPIATE ADDICTION; PERFORMANCE MEASUREMENT SYSTEM; PRIORITY JOURNAL; QUESTIONNAIRE; SUBSTANCE ABUSE;

CLINICAL CODING; DATA COLLECTION; HEALTH SERVICES ACCESSIBILITY; HUMANS; INSURANCE CLAIM REVIEW; OUTPATIENTS; POLICY MAKING; QUALITY INDICATORS, HEALTH CARE; QUALITY OF HEALTH CARE; SUBSTANCE-RELATED DISORDERS;

EID: 78649796058     PISSN: 07405472     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jsat.2010.08.005     Document Type: Article

References (46)

1. AHRQ National Healthcare Quality Report 2008, Agency for Healthcare Research and Quality, Rockville, MD, March 2009 Report No.: AHRQ Publication 090001.
2. Albright J., Ciaverelli R., Essess A., et al. Psychiatrist characteristics that influence use of buprenorphine medication-assisted treatment. Journal of Addiction Medicine 2010, (e-pub ahead of print).
3. AMA. (2008). Substance use disorders physician performance measurement set Chicago, IL: American Psychiatric Association (APA), Physician Consortium for Performance Improvement® (PCPI), National Committee for Quality Assurance (NCQA).
4. Barnett P.G. Comparison of costs and utilization among buprenorphine and methadone patients. Addiction 2009, 104:982-992.
5. Blumenthal D. Launching HITECH. New England Journal of Medicine 2010, 362:382-385.
6. DesRoches C.M., Campbell E.G., Rao S.R., et al. Electronic health records in ambulatory care-A national survey of physicians. New England Journal of Medicine 2008, 359:50-60.
7. Donabedian A. The quality of care. How can it be assessed. Journal of the American Medical Association 1988, 260:1743-1748.
8. Fixsen D.L., Blase K.A. Creating new realities: Program development and dissemination. Journal of Applied Behavior Analysis 1993, 26:597-615.
9. Fuller B.E., Rieckmann T., McCarty D., et al. Adoption of naltrexone to treat alcohol dependence. Journal of Substance Abuse Treatment 2005, 28:273-280.
10. Garnick D., Lee M., Horgan C., et al. 2010.
11. Garnick D.W., Lee M.T., Chalk M., et al. Establishing the feasibility of performance measures for alcohol and other drugs. Journal of Substance Abuse Treatment 2002, 23:375-385.
12. Garnick D.W., Lee M.T., Horgan C.M., et al. Adapting Washington Circle performance measures for public sector substance abuse treatment systems. Journal of Substance Abuse Treatment 2009, 36:265-277.
13. Gelber S. A. (in press). State Financing For Medication-Assisted Treatment: Results And Observation From A 50-State NCSL/AVISA Survey (March 2008) National Council of State Legislators.
14. Harris A. H., Kivlahan D., Bowe T., et al. Developing and Validating Process Measures of Health Care Quality: An Application to Alcohol Use Disorder Treatment. Medical Care, 47, 1244-1250.
15. Harris A.H.S., Humphreys K., Bowe T., et al. Measuring the quality of substance use disorder treatment: Evaluating the validity of the Department of Veterans Affairs continuity of care performance measure. Journal of Substance Abuse Treatment 2009, 36:294-305.
16. Harris A.H.S., Humphreys K., Finney J.W. Veterans Affairs facility performance on Washington Circle indicators and casemix-adjusted effectiveness. Journal of Substance Abuse Treatment 2007, 33:333-339.
17. Harris A.H.S., Kivlahan D., Bowe T., et al. Pharmacotherapy of alcohol use disorders in the Veterans Health Administration. Psychiatric Services 2010, 61:392-398.
18. Horgan C.M., Garnick D. The quality of care for adults with mental and addictive disorders: Issues in performance measurement. Background paper for the Institute of Medicine 2005, Institute for Behavioral Health, Heller School for Social Policy and Management, Brandeis University, Waltham.
19. Horgan C.M., Reif S., Hodgkin D., et al. Availability of addiction medications in private health plans. Journal of Substance Abuse Treatment 2008, 34:147-156.
20. Humphreys K.H., Harris A.H.S., Kivlahan D. Performance monitoring of substance abuse disorder intervensions in the Veterans Health Administration. American Journal of Drug and Alcohol Abuse 2009, 35:123-127.
21. Knudsen H.K., Ducharme L.J., Roman P.M. The adoption of medications in substance abuse treatment: Associations with organizational characteristics and technology clusters. Drug Alcohol Depend 2007, 87:164-174.
22. Kresina T.F., Litwin A., Marion I., et al. United States Government oversight and regulation of medication assisted treatment for the treatment of opioid dependence. Journal of Deug Policy Analysis 2009, 2:1-23.
23. Lindenauer P.K., Remus D., Roman S., et al. Public reporting and pay for performance in hospital quality improvement. The New England Journal of Medicine 2007, 356:486-496.
24. Mark T.L., Coffey R.M., McKusick D.R., et al. National estimates of expenditures for mental health services and substance abuse treatment, 1991-2001 2005, Substance Abuse and Mental Health Services Administration, Rockville, MD, SAMHSA Publication No. SMA 05-3999.
25. Mark T.L., Kassed C.A., Vandivort-Warren R., et al. Alcohol and opioid dependence medications: Prescription trends, overall and by physician specialty. Drug Alcohol Depend 2009, 99:345-349.
26. Mark T.L., Kranzler H.R., Poole V.H., et al. Barriers to the use of medications to treat alcoholism. American Journal on Addictions 2003, 12:281-294.
27. Mark T.L., Kranzler H.R., Song X. Understanding US addiction physicians' low rate of naltrexone prescription. Drug and Alcohol Dependence 2003, 71:219-228.
28. McCorry F., Garnick D.W., Bartlett J., et al. Developing performance measures for alcohol and other drug services in managed care plans. Washington Circle Group. Joint Commission Journal on Quality Improvement 2000, 26:633-643.
29. McLellan A.T., Kemp J., Brooks A., et al. Improving public addiction treatment through performance contracting: The Delaware experiment. Health Policy 2008, 87:296-308.
30. McLellan A.T., Lewis D.C., O'Brien C.P., et al. Drug dependence, a chronic medical illness: Implications for treatment, insurance, and outcomes evaluation. Journal of the American Medical Association 2000, 284:1689-1695.
31. Missouri Requires Providers to Offer Medication-Assisted Treatment Alcoholism & Drug Abuse Weekly (ADAW) 2009, 21:3-4.
32. NQF Evidence-based treatment practices for substance use disorders, October 2005 2005, National Quality Forum, Washington DC.
33. NQF 2007.
34. Oros M The Baltimore Buprenorphine Initiative 2009, Washington DC.
35. Rogers E.M. Diffusion of innovations 2003, Free Press, New York. Fifth Ed.
36. SAMHSA National Outcome Measures 2010, http://www.nationaloutcomemeasures.samhsa.gov/NOMS.aspx?menuID=2.
37. SAMHSA Tip 28: Naltrexone and alcoholism treatment 1998.
38. SAMHSA TIP 40: Clinical guidelines for the use of buprenorphine in the treatment of opioid addiction 2004, U.S. Department of Health and Human Services, Publication no. (SMA) 04-3939, Washington DC.
39. Stewart M., Horgan C. Health services and financing of treatment. Alcohol Research and Health 2010, (in press).
40. Stringer M Missouri's state and provider partnership for implementing medication assisted treatment 2008, Washington DC.
41. Systems B.S.A. The Baltimore Buprenorphine Initiative Second Interim Progress Report June 2008, Baltimore City Health Department, Baltimore.
42. Thatcher J Value options: Massachusetts Medicaid behavioral carve out 2009.
43. Thomas C.P., Wallack S.S., Lee S., et al. Research to practice: Adoption of naltrexone in alcoholism treatment. Journal of Substance Abuse Treatment 2003, 24:1-11.
44. Un H. Medication assisted treatment for alcohol use disorder 2008.
45. VHA VHA Handbook: 1160.01: Uniform mental health services in VA medical centers and clinics 2008, Washington DC.
46. VHA VHA/ DOD clinical practice guideline for the management of substance use disorders: guideline summary July 2009, Department of Veterans Affairs Department of Defense, Washington DC.